Safety and efficacy of ibutilide in heart transplant recipients

J Heart Lung Transplant. 2009 May;28(5):505-7. doi: 10.1016/j.healun.2009.02.013.

Abstract

In this report we describe our experience with ibutilide, a relatively new Class III anti-arrhythmic agent, in 8 heart transplant patients with supraventricular tachycardia in various settings (3 patients with rejection, 2 after endomyocardial biopsy). Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications.

MeSH terms

  • Adolescent
  • Adult
  • Anti-Arrhythmia Agents / therapeutic use*
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / physiopathology
  • Atrial Flutter / drug therapy
  • Atrial Flutter / physiopathology
  • Atrioventricular Block / drug therapy
  • Atrioventricular Block / physiopathology
  • Biopsy
  • Electrocardiography / drug effects
  • Endocardium / pathology
  • Female
  • Graft Rejection / drug therapy
  • Graft Rejection / pathology
  • Graft Rejection / physiopathology
  • Heart Transplantation / physiology*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Myocardium / pathology
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / physiopathology
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use*
  • Tachycardia, Supraventricular / drug therapy*
  • Tachycardia, Supraventricular / physiopathology
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • Sulfonamides
  • ibutilide